Biosimilars approved in Costa Rica

Biosimilars/General | Posted 03/09/2021 post-comment0 Post your comment

In Costa Rica, the regulatory body responsible for the approval of biologicals is the Ministry of Health.

MinSalud Costa Rica V21I03

A sanitary registration is a control mechanism that entails the verification of requirements associated with the quality and safety of products of sanitary interest, with the objective of contributing to protect the health of the Costa Rican population.

Among the products that require sanitary registration for their importation, commercialization and consumption are food, cosmetics, biomedical equipment and material, medicines, pesticides for household and professional use, natural products with medicinal qualities, hygiene products, dangerous chemical products, including inks used for tattooing.

The legal framework was established in Costa Rica through the technical regulation RTCR 440:2010, Regulation on the Registration and Control of Biological Medicinal Products Nº 37006-S, which came into force on 23 September 2012.

The Ministry of Health Costa Rica defines a biosimilar as the medicine that has been demonstrated through the biosimilarity exercise, that it is similar in terms of quality, safety and efficacy to the reference biological medicine.

To date, the Ministry of Health Costa Rica has approved two biosimilars, Epoyet™ and Heberon Alfa R [1], within the product classes of: 1) erythropoiesis-stimulating agent; and 2) granulocyte colony-stimulating factor, see Table 1.

Table 1: Biosimilars approved by the Ministry of Health Costa Rica
Product name Active substance Therapeutic area Manufacturer/ Company name Country of origin
Epoyet™ erythropoietin anaemia Biosidus Argentina
Heberon
Alfa R
filgrastim antiviral
neoplasias
solid tumours
fibrosis and central nervous system diseases
Sandoz Cuba

  
Ior Epocim, a biomimic of erythropoietin, is also approved in Costa Rica for use as an erythropoiesis stimulating agent.

Biomimics are intended copies, unregulated biologicals, biocopies, which cannot be considered biosimilars unless they have been reviewed and approved by the appropriate regulatory agencies in accordance with the international guidelines provided by the World Health Organization (WHO) for the approval of biosimilars [2].

Editor’s comment
European Medicines Agency regulatory requirements ensure the same high standards of quality, safety, and efficacy for biosimilars as for originator biologicals, and also include a rigorous comparability exercise with the reference product but they are not universally accepted by regulatory bodies outside of the European Union (EU). It should be noted that ‘biosimilars’ approved in Costa Rica might not have been authorized if they had been subjected to the strict regulatory processes required for approval of biosimilars in the EU.

Related articles
The biosimilars market in Latin America: a summary

Similar biotherapeutic products approved and marketed in Latin America

LATIN AMERICAN FORUM

The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: Biosimilares e intercambiabilidad en oncología

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Biosimilares e intercambiabilidad en oncología

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

  
References
1. Ortiz-Prado E, Ponce-Zea J, Vasconez JE, et al. Current trends for biosimilars in the Latin American market. Generics Biosimilars Initiative Journal (GaBI Journal). 2020;9(2):64-74. doi:10.5639/gabij.2020.0902.011
2. GaBI Online - Generics and Biosimilars Initiative. Glosario de términos principales [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Sep 3].

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: Ministerio de Salud Costa Rica

comment icon Comments (0)
Post your comment
Related content
Off-patent biologicals/Biomimics approved in Bolivia
AGEMED V21I17MN
Biosimilars/General Posted 17/09/2021
Glosario de términos principales
20 AA010933
Biosimilars/General Posted 10/09/2021
Interactive map for interchangeable biosimilars
US map V18D13
Biosimilars/General Posted 10/09/2021
Biosimilars, innovation in the treatment of chronic disease
Health Budget 3
Biosimilars/General Posted 27/08/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010